Bingpian Tech Secures Angel Funding to Advance Digital Therapeutics Platform for Allergy Management Based on Environmental Intervention

VCBeat has learned that Bingpian Technology recently completed its angel-round financing, invested by Yuansheng Beijing Angel Fund. The proceeds from this round will be primarily allocated to three areas: product development, acquisition of regulatory approvals, and team expansion.

Founded in 2016, Bingpian Technology is dedicated to digital therapeutics for environmental dust mite prevention and control. It has built a digital therapeutics platform focused on the field of allergies and established a comprehensive database covering the entire patient journey from diagnosis to treatment.To date, Bingpian Technology has accumulated over 1,000 clinical data entries and more than 5,000 household environmental data records, and has established collaborative partnerships with large public Grade A tertiary hospitals across all provinces and municipalities in China.

Bingpian Tech’s One-Stop Solution for Allergic Diseases (Image provided by Bingpian Tech)

“In the treatment guidelines for allergic diseases, environmental control remains a gap,” said Jiang Haibo, founder of Bingpian Technology. By focusing on environmental prevention and control, Bingpian Technology has developed a comprehensive digital therapeutic solution for allergic conditions. Through environmental monitoring and mitigation, coupled with precise data recording throughout the entire patient care journey, this approach enables patients to effectively manage their symptoms without medication.

“The number of allergy patients in China is huge, but the coverage rate remains very low, so there is vast room for market growth,” said Jiang Haibo.

What are the facts?

According to Puhua Youce’s “Special Research Report on the Allergy Diagnosis Market and Investment Feasibility Assessment (2021–2026),”The global allergy diagnostics market was valued at approximately USD 4.26 billion in 2019 and is projected to reach USD 5.75 billion by 2022.

Furthermore, the report explicitly points out that China’s allergy diagnostics market is poised for rapid expansion. This opportunity arises from the country’s large population base and substantial number of allergy patients, coupled with low rates of testing and clinical consultation, which have resulted in a mismatch between the market size for allergy diagnosis and treatment and the actual patient volume. Driven by multiple factors—including the continuous advancement of national macro-level policies, growing health awareness, and steady improvements in disease diagnosis and treatment capabilities—the domestic allergy diagnostics industry holds significant potential for growth.

Therefore,The report forecasts that the size of China's allergy diagnostics market will reach RMB 930 million in 2023, with a projected compound annual growth rate (CAGR) of 15% from 2020 to 2023.

However, according to the treatment guidelines for allergic diseases issued by the World Allergy Organization (WAO), a comprehensive management plan for allergic diseases should include patient education, environmental control, pharmacotherapy, and immunotherapy. Among these, environmental control encompasses two aspects: environmental assessment and environmental intervention.

“According to this ‘four-in-one’ treatment guideline, patients need to undergo environmental testing while undergoing allergen testing. Only after identifying all allergens (both internal and external environmental factors) should they proceed with pharmacological treatment, desensitization therapy, or environmental interventions,” said Jiang Haibo. Unfortunately,“In previous treatment regimens, patients underwent only allergen testing before directly initiating pharmacological therapy, with no assessment or intervention for environmental allergens. ‘This is an incomplete therapeutic approach.’”

Therefore, Bingpian Technology is targeting this market opportunity and has begun to position its allergy treatment business from the perspective of environmental prevention and control.

Interestingly, Jiang Haibo, the founder of Bingpian Technology, does not have a medical background; rather, he is a serial internet entrepreneur with a strong legal background, butIt entered the mobile healthcare sector in 2013, focusing on oncology as a vertical specialty, and has fully experienced and witnessed the entire development process of mobile healthcare in China.

“As a representative of the Star Future Entrepreneurship Camp participants,Jiang Haibo embodies the dual identities of a traditional TMT entrepreneur and a healthcare entrepreneur.“Wu Lili, CEO of Fosun Xingweilai Research Institute, stated thatBingpian Technology not only prioritizes the iterative innovation of digital technologies but also, grounded in the foundational logic of evidence-based medicine, delivers a refreshing product experience for patients and users.

Photo of Jiang Haibo during his participation in the Star Future Entrepreneurship Camp (Image courtesy of Bingpian Technology)

As for why the allergy sector was chosen, Jiang Haibo stated that there were mainly two factors: on one hand, through accompanying family members to medical consultations, he intuitively felt that allergic diseases received relatively low attention in China, and the maturity of disease treatment logic, methods, and protocols was still in its early stages; on the other hand, “at that time, other sectors were already highly crowded, while allergology was a small department in hospitals, with low visibility but a large patient base,”"Therefore, we decided to enter this blue-ocean sector and have been continuously advancing our efforts since 2016."

PwC’s recently released report, “Review and Outlook of M&A Activities in China’s Greater Health Industry from 2013 to the First Half of 2021,” also mentioned:Amid the digitalization trend in healthcare, digital therapeutics (DTx), as an emerging and popular sector, are poised to reshape the prevention, treatment, and disease management of certain conditions. Focusing on the vertical specialty of allergies also provides new directions for exploration and practice within China’s DTx landscape.As digital healthcare business models continue to innovate and evolve, PwC will remain committed to providing specialized support and assistance to innovators and investors.

According to Jiang Haibo,To date, Bingpian Technology has developed two core products: environmental therapy and an integrated software solution for the precise diagnosis, treatment, and prevention/control of allergic diseases based on environmental therapy. These offerings are gradually evolving into a digital therapeutics platform targeting allergic rhinitis and asthma.

“Through this approach, we can not only achieve the combined detection recommended in the WAO guidelines but also help patients with dust mite-induced allergic rhinitis and asthma attain a disease treatment efficacy rate of over 50%,” said Jiang Haibo.

Jiang Haibo also revealed to VCBeat that due to the complex and variable environmental factors, actual testing and operational costs are very high. Therefore, although the World Allergy Organization (WAO) clearly stated the effectiveness and necessity of environmental therapy in clinical practice in its guidelines published as early as 2013, no mature precedents have emerged domestically or internationally for reference due to the inability to implement it in practice.

To this end, the team at Bingpian Technology spent nearly two years visiting dozens of large Grade A tertiary hospitals across 15 provinces and municipalities in China. They actively engaged with experts, professors, and clinicians nationwide to seek advice and medical support, devoted substantial time to reviewing domestic and international literature, designing clinical study protocols, and conducting real-world studies to accumulate academic and practical experience. Ultimately, they successfully developed a digital therapy based on #EnvironmentalDustMiteControl#.

Building on this foundation, Bingpian Technology has launched an integrated software solution for the precise diagnosis, treatment, and prevention of allergic diseases. It has gradually evolved into a digital health platform specializing in allergy care and established a comprehensive database covering the entire patient journey from diagnosis to treatment, thereby enabling full-course management for patients with allergies.

Schematic Diagram of Bingpian Tech’s AI Diagnosis and Treatment System for Allergic Diseases (Image provided by Bingpian Tech)

“It is precisely because we launched products for environmental diagnosis and treatment as well as environmental prevention and control, thereby accumulating extensive clinical and environmental data, that Bingpian Technology has been able to naturally extend into whole-course patient management,” said Jiang Haibo, highlighting this as the company’s product logic.

“The team’s resilience and deep understanding of digital therapeutics were the primary reasons for our successful fundraising,” Jiang Haibo told VCBeat.

During the 2020 pandemic, the development of most industries in China hit the pause button. Some companies endured a harsh winter, and Bingpian Technology was no exception.

“Entrepreneurship is a marathon. The attitude with which a team confronts difficulties, or even dire straits, is crucial to the future development of the enterprise. During the pandemic, we faced significant hardships, but our entire team persevered with immense courage and determination,” said Jiang Haibo. “I believe this was a key factor in our successful fundraising.”

Furthermore,Bingpian Technology has been deeply rooted in the niche sector of allergy management for six years, demonstrating a thorough and insightful understanding of the industry.

“Digital therapeutics are both highly popular and novel; it is crucial to correctly understand and apply them in practice,” said Jiang Haibo., digital therapeutics belongs to the interdisciplinary field of internet and healthcare. "Years of practical experience in the internet industry, followed by our entry into the vertical disease sectors of oncology and allergy, have given us profound understanding and insights into both the digital and medical domains."

Focusing on the product itself,Bingpian Technology has independently developed diagnostic reagents that demonstrate excellent sensitivity and specificity, offering superior cost-effectiveness compared to the benchmark company Indoor’s diagnostic reagents. Furthermore, through scientific research collaborations, Bingpian Technology has partnered with major Grade A tertiary hospitals across various provinces and cities in China, thereby obtaining reliable clinical data and accumulating a significant amount of regional environmental data, thus establishing a robust technical barrier.

Regarding future strategic planning, Jiang Haibo stated that the direction of Bingpian Technology’s digital therapeutics platform is clear.“The allergy care market is vast, and patients require more diverse and comprehensive diagnostic and treatment solutions. Through Bingpian Technology’s platform, we aim to collaborate with partners across the industry chain—including physicians, pharmaceutical companies, and medical device manufacturers—to deliver more efficient and precise services to patients with allergic diseases.”